These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
72 related articles for article (PubMed ID: 16931012)
1. Discovery and preliminary structure-activity relationship studies of novel benzotriazine based compounds as Src inhibitors. Noronha G; Barrett K; Cao J; Dneprovskaia E; Fine R; Gong X; Gritzen C; Hood J; Kang X; Klebansky B; Li G; Liao W; Lohse D; Mak CC; McPherson A; Palanki MS; Pathak VP; Renick J; Soll R; Splittgerber U; Wrasidlo W; Zeng B; Zhao N; Zhou Y Bioorg Med Chem Lett; 2006 Nov; 16(21):5546-50. PubMed ID: 16931012 [TBL] [Abstract][Full Text] [Related]
2. Three-dimensional quantitative structure-activity relationship studies on novel series of benzotriazine based compounds acting as Src inhibitors using CoMFA and CoMSIA. Gueto C; Ruiz JL; Torres JE; Méndez J; Vivas-Reyes R Bioorg Med Chem; 2008 Mar; 16(5):2439-47. PubMed ID: 18065233 [TBL] [Abstract][Full Text] [Related]
3. Novel aminomethylindole derivatives as inhibitors of pp60c-Src tyrosine kinase: synthesis and biological activity. Işgör YG; Kiliç Z; Olgen S Chem Biol Drug Des; 2008 Dec; 72(6):599-604. PubMed ID: 19090928 [TBL] [Abstract][Full Text] [Related]
4. Synthesis and activity of novel 5-substituted pyrrolo[2,3-d]pyrimidine analogues as pp60(c-Src) tyrosine kinase inhibitors. Olgen S; Isgör YG; Coban T Arch Pharm (Weinheim); 2008 Feb; 341(2):113-20. PubMed ID: 18214841 [TBL] [Abstract][Full Text] [Related]
5. Synthesis and pp60c-Src tyrosine kinase inhibitory activities of novel indole-3-imine and amine derivatives substituted at N1 and C5. Kiliç Z; Isgör YG; Olgen S Arch Pharm (Weinheim); 2009 Jun; 342(6):333-43. PubMed ID: 19475593 [TBL] [Abstract][Full Text] [Related]
6. Structure-based design of novel nonpeptide inhibitors of the Src SH2 domain:phosphotyrosine mimetics exploiting multifunctional group replacement chemistry. Sundaramoorthi R; Kawahata N; Yang MG; Shakespeare WC; Metcalf CA; Wang Y; Merry T; Eyermann CJ; Bohacek RS; Narula S; Dalgarno DC; Sawyer TK Biopolymers; 2003; 71(6):717-29. PubMed ID: 14991680 [TBL] [Abstract][Full Text] [Related]
7. Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. Boschelli DH; Wu B; Ye F; Wang Y; Golas JM; Lucas J; Boschelli F J Med Chem; 2006 Dec; 49(26):7868-76. PubMed ID: 17181170 [TBL] [Abstract][Full Text] [Related]
8. Synthesis and SAR of new pyrrolo[2,1-f][1,2,4]triazines as potent p38 alpha MAP kinase inhibitors. Wrobleski ST; Lin S; Hynes J; Wu H; Pitt S; Shen DR; Zhang R; Gillooly KM; Shuster DJ; McIntyre KW; Doweyko AM; Kish KF; Tredup JA; Duke GJ; Sack JS; McKinnon M; Dodd J; Barrish JC; Schieven GL; Leftheris K Bioorg Med Chem Lett; 2008 Apr; 18(8):2739-44. PubMed ID: 18364256 [TBL] [Abstract][Full Text] [Related]
9. Structural basis for the activity of pp60(c-src) protein tyrosine kinase inhibitors. Prabhu NV; Siddiqui SA; McMurray JS; Pettitt BM Biopolymers; 2001 Sep; 59(3):167-79. PubMed ID: 11391566 [TBL] [Abstract][Full Text] [Related]
10. In silico screening and biological evaluation of inhibitors of Src-SH3 domain interaction with a proline-rich ligand. Atatreh N; Stojkoski C; Smith P; Booker GW; Dive C; Frenkel AD; Freeman S; Bryce RA Bioorg Med Chem Lett; 2008 Feb; 18(3):1217-22. PubMed ID: 18083027 [TBL] [Abstract][Full Text] [Related]
11. The design and preliminary structure-activity relationship studies of benzotriazines as potent inhibitors of Abl and Abl-T315I enzymes. Cao J; Fine R; Gritzen C; Hood J; Kang X; Klebansky B; Lohse D; Mak CC; McPherson A; Noronha G; Palanki MS; Pathak VP; Renick J; Soll R; Zeng B; Zhu H Bioorg Med Chem Lett; 2007 Nov; 17(21):5812-8. PubMed ID: 17827012 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of new indole and bromoindole derivatives as pp60(c-Src) tyrosine kinase inhibitors. Kiliç Z; Işgör YG; Olgen S Chem Biol Drug Des; 2009 Oct; 74(4):397-404. PubMed ID: 19691468 [TBL] [Abstract][Full Text] [Related]
13. The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors. Alvarez RH; Kantarjian HM; Cortes JE Cancer; 2006 Oct; 107(8):1918-29. PubMed ID: 16986126 [TBL] [Abstract][Full Text] [Related]
14. Development of prodrug 4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl benzoate (TG100801): a topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degeneration. Palanki MS; Akiyama H; Campochiaro P; Cao J; Chow CP; Dellamary L; Doukas J; Fine R; Gritzen C; Hood JD; Hu S; Kachi S; Kang X; Klebansky B; Kousba A; Lohse D; Mak CC; Martin M; McPherson A; Pathak VP; Renick J; Soll R; Umeda N; Yee S; Yokoi K; Zeng B; Zhu H; Noronha G J Med Chem; 2008 Mar; 51(6):1546-59. PubMed ID: 18311895 [TBL] [Abstract][Full Text] [Related]
15. SAR of carbon-linked, 2-substituted purines: synthesis and characterization of AP23451 as a novel bone-targeted inhibitor of Src tyrosine kinase with in vivo anti-resorptive activity. Shakespeare WC; Wang Y; Bohacek R; Keenan T; Sundaramoorthi R; Metcalf C; Dilauro A; Roeloffzen S; Liu S; Saltmarsh J; Paramanathan G; Dalgarno D; Narula S; Pradeepan S; van Schravendijk MR; Keats J; Ram M; Liou S; Adams S; Wardwell S; Bogus J; Iuliucci J; Weigele M; Xing L; Boyce B; Sawyer TK Chem Biol Drug Des; 2008 Feb; 71(2):97-105. PubMed ID: 18179464 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of Bcr-Abl phosphorylation and induction of apoptosis by pyrazolo[3,4-d]pyrimidines in human leukemia cells. Manetti F; Pucci A; Magnani M; Locatelli GA; Brullo C; Naldini A; Schenone S; Maga G; Carraro F; Botta M ChemMedChem; 2007 Mar; 2(3):343-53. PubMed ID: 17295370 [TBL] [Abstract][Full Text] [Related]
17. RACK1 inhibits colonic cell growth by regulating Src activity at cell cycle checkpoints. Mamidipudi V; Dhillon NK; Parman T; Miller LD; Lee KC; Cartwright CA Oncogene; 2007 May; 26(20):2914-24. PubMed ID: 17072338 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and SAR studies of novel antifungal 1,2,3-triazines. Hunt JC; Briggs E; Clarke ED; Whittingham WG Bioorg Med Chem Lett; 2007 Sep; 17(18):5222-6. PubMed ID: 17656087 [TBL] [Abstract][Full Text] [Related]
19. Synthesis, structure and hypoxic cytotoxicity of 3-amino-1,2,4-benzotriazine-1,4-dioxide derivatives. Jiang F; Weng Q; Sheng R; Xia Q; He Q; Yang B; Hu Y Arch Pharm (Weinheim); 2007 May; 340(5):258-63. PubMed ID: 17464965 [TBL] [Abstract][Full Text] [Related]
20. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity. Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]